2024
Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project
Javanbakht A, Stringer S, Anderson H, Hamilton E, Philip A, Waller E, Langston A, Joseph N, Roback J, Schneider T, Sullivan H, Hendrickson J. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project. Journal Of Clinical Apheresis 2024, 39: e22127. PMID: 38803152, DOI: 10.1002/jca.22127.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzylaminesBlood Component RemovalCyclamsFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansMaleMiddle AgedMultiple MyelomaPeripheral Blood Stem Cell TransplantationPlatelet CountRetrospective StudiesTransplantation, AutologousConceptsStem cell collectionPlatelet countG-CSFMultiple myelomaAutologous peripheral blood stem cell collectionApheresis collectionsPeripheral blood stem cell collectionAutologous stem cell collectionBlood stem cell collectionCell collectionPre-emptive plerixaforBaseline platelet countTransplant doseAutologous collectionApheresisPatientsMedical recordsPlerixaforCollection goalDay of collectionQuality improvement initiativesMyelomaPoor mobilityPlateletCount
2023
P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Roback J, Neish A, Fasano R, Stowell S. P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease. Transfusion 2023, 63: 159a-160a. DOI: 10.1111/trf.204_17554.Peer-Reviewed Original ResearchEnhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, PMCID: PMC10751105, DOI: 10.1111/bjh.18899.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCOVID-19 vaccinationAntibody responseCell diseaseSARS-CoV-2 vaccinationIgG immune responseSimilar antibody responsesOptimal vaccination strategyIgG titresIgG responsesVaccination strategiesImmune responseSCD controlsGeneral populationPatientsVaccinationDiseaseResponseCohortTitresEpidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroids
2022
A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease
Goshua G, Hauser R, Tormey C, Pandya A, Hendrickson J. A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease. Blood 2022, 140: 2147-2148. DOI: 10.1182/blood-2022-169099.Peer-Reviewed Original Research
2021
Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
Madany E, Lee J, Halprin C, Seo J, Baca N, Majlessipour F, Hendrickson JE, Pepkowitz SH, Hayes C, Klapper E, Gibb DR. Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease. EJHaem 2021, 2: 700-710. PMID: 35128535, PMCID: PMC8813163, DOI: 10.1002/jha2.270.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsSickle cell diseaseCell diseaseRace-matched healthy controlsType 1 interferon responseFrequency of alloimmunizationNon-alloimmunized patientsBlood mononuclear cellsType 1 interferonExpression of ISGsGene scoreNonalloimmunized patientsRBC alloimmunizationPlasma cytokinesSCD patientsMononuclear cellsHealthy controlsHigh prevalenceBlood leukocytesAlloimmunizationViral immunityPatientsIFNISG expressionInterferon responsePotential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease
Madany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson JE, Gibb DR. Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers In Medicine 2021, 8: 679030. PMID: 34368185, PMCID: PMC8339405, DOI: 10.3389/fmed.2021.679030.Peer-Reviewed Original ResearchSickle cell diseaseCOVID-19 severityIFNα/βType 1 interferonCell diseaseSARS-CoV-2 infectionType 1 interferon responseCorona Virus Disease-19 (COVID-19) pandemicCohort of patientsMajority of patientsInterferon gene signatureIFNα/β productionRace-matched controlsDisease-19 pandemicCOVID-19Express elevated levelsMajority of evidenceSCD diseaseSevere sequelaeChronic inflammationFavorable outcomeVariable progressionClinical consequencesGeneral populationPatients
2020
A potential association of an interferon gene signature with RBC alloimmunization in sickle cell disease
Madany E, Kadi N, Pandya S, Hendrickson J, Gibb D. A potential association of an interferon gene signature with RBC alloimmunization in sickle cell disease. The Journal Of Immunology 2020, 204: 145.18-145.18. DOI: 10.4049/jimmunol.204.supp.145.18.Peer-Reviewed Original ResearchSickle cell diseaseInterferon-stimulated genesRBC alloimmunizationMore alloantibodiesGene signatureSCD patientsCell diseaseFrequency of alloimmunizationChronic inflammatory stateInterferon gene signatureProduction of alloantibodiesMultiple interferon-stimulated genesType 1 interferonMyxovirus resistance protein 1Resistance protein 1Alloimmunization frequencyCompatible RBCsRBC transfusionInflammatory stateMxA expressionDisease populationTransfusion modelAlloimmunizationPatientsSiglec-1
2019
Chapter 57 Platelet Transfusion Refractory Patients
Tormey C, Hendrickson J. Chapter 57 Platelet Transfusion Refractory Patients. 2019, 361-364. DOI: 10.1016/b978-0-12-813726-0.00057-x.ChaptersHuman leukocyte antigenPlatelet refractorinessRefractory patientsPlatelet transfusion-refractory patientsRecipient human leukocyte antigenClass I human leukocyte antigenPlatelet refractory patientsPlatelet transfusion supportManagement of patientsHLA-B antigensCauses of refractorinessHLA alloantibodiesNonimmune causesHost diseaseTransfusion supportLeukocyte antigenOptimal carePatientsClinical teamTransfusion servicesMultidisciplinary approachRefractorinessBlood suppliersPlateletsAntigenChapter 49 Neonatal and Pediatric Transfusion Medicine
Zerra P, Hendrickson J, Josephson C. Chapter 49 Neonatal and Pediatric Transfusion Medicine. 2019, 295-299. DOI: 10.1016/b978-0-12-813726-0.00049-0.Peer-Reviewed Original ResearchChapter 53 Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation
Rutter S, Hendrickson J. Chapter 53 Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation. 2019, 337-341. DOI: 10.1016/b978-0-12-813726-0.00053-2.Peer-Reviewed Original ResearchSolid organ transplantationOrgan transplantationHematopoietic stem cellsOptimal transfusion triggerTransfusion adverse eventsBlood product selectionStem cellsGranulocyte transfusionsAdverse eventsPlatelet refractorinessTransfusion supportTransfusion triggerTransfusion managementTransplant servicesRhD typeOptimal outcomesTransfusionPatientsTransplantationCellsRecipientsRefractorinessChapter 56 Management of Patients Who Refuse Blood Transfusion
Bahar B, Hendrickson J. Chapter 56 Management of Patients Who Refuse Blood Transfusion. 2019, 357-360. DOI: 10.1016/b978-0-12-813726-0.00056-8.Peer-Reviewed Original ResearchBlood productsRed blood cellsBlood transfusionBlood management programManagement of patientsJehovah's Witness faithCertain blood componentsBlood lossCoagulation defectsMedical recordsPatientsAnemia toleranceTransfusionBlood componentsBlood cellsRBC productionExcellent communicationManagement programCliniciansHemostasisGranulocytesChapter 65 Transfusion-Associated Circulatory Overload
Gokhale A, Hendrickson J. Chapter 65 Transfusion-Associated Circulatory Overload. 2019, 401-404. DOI: 10.1016/b978-0-12-813726-0.00065-9.Peer-Reviewed Original ResearchTransfusion-associated circulatory overloadCirculatory overloadLonger hospital courseCardiogenic pulmonary edemaTransfusion-related fatalitiesBlood product infusionSecond leading causeCommon transfusion reactionsTransfused volumeDiuretic useHospital coursePulmonary edemaLeading causeTransfusion reactionsBlood productsProduct infusionHigh riskPreventative strategiesPrevention strategiesJudicious usePatientsOverloadMorbidityEdemaInfusion
2017
A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia
Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.Peer-Reviewed Original ResearchConceptsDrug-induced immune thrombocytopeniaAutoimmune hemolytic anemiaPlatelet-reactive antibodiesImmune thrombocytopeniaThrombotic microangiopathyAdministration of oxaliplatinCycles of FOLFOXOxaliplatin-induced thrombocytopeniaYear old manAnti-RBC IgGEvans syndromeAntibody testingFirst admissionIgM antibodiesSignificant thrombocytopeniaIgG antibodiesHemolytic anemiaThrombocytopeniaLeucovorinPlatelet IgGOlder menOxaliplatinSyndromeBlood centersPatients
2016
Incidence and clinical characteristics of transfusion‐associated circulatory overload using an active surveillance algorithm
Roubinian N, Hendrickson J, Triulzi D, Gottschall J, Chowdhury D, Kor D, Looney M, Matthay M, Kleinman S, Brambilla D, Murphy E, Study‐III T. Incidence and clinical characteristics of transfusion‐associated circulatory overload using an active surveillance algorithm. Vox Sanguinis 2016, 112: 56-63. PMID: 28001313, PMCID: PMC5257198, DOI: 10.1111/vox.12466.Peer-Reviewed Original ResearchConceptsTransfusion-associated circulatory overloadPulmonary edemaClinical characteristicsCirculatory overloadCases of TACOIncidence of TACOClinical diagnosisElectronic screening algorithmExpert panelExpert panel diagnosisMerit further evaluationAdult inpatientsClinical parametersImproved oxygenationActive surveillanceAcademic hospitalChest radiographsPanel diagnosisPatientsEdemaFurther evaluationIncidenceStudy designPilot studyDiagnosis
2013
Chapter 54 Management of Patients Who Refuse Blood Transfusion
Hendrickson J. Chapter 54 Management of Patients Who Refuse Blood Transfusion. 2013, 357-360. DOI: 10.1016/b978-0-12-397164-7.00054-9.Peer-Reviewed Original ResearchChapter 51 Transfusion of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation
Hendrickson J. Chapter 51 Transfusion of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation. 2013, 337-342. DOI: 10.1016/b978-0-12-397164-7.00051-3.Peer-Reviewed Original ResearchChapter 55 Platelet Transfusion Refractory Patients
Hendrickson J. Chapter 55 Platelet Transfusion Refractory Patients. 2013, 361-365. DOI: 10.1016/b978-0-12-397164-7.00055-0.Peer-Reviewed Original ResearchChapter 47 Neonatal and Pediatric Transfusion Medicine
Hendrickson J, Josephson C. Chapter 47 Neonatal and Pediatric Transfusion Medicine. 2013, 301-305. DOI: 10.1016/b978-0-12-397164-7.00047-1.Peer-Reviewed Original Research
2012
Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations
Zimring J, Stowell S, Johnsen J, Hendrickson J. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations. Transfusion Clinique Et Biologique 2012, 19: 125-131. PMID: 22682308, DOI: 10.1016/j.tracli.2012.03.002.Peer-Reviewed Original ResearchConceptsImmune systemLarge observational studiesMinority of recipientsHuman immune systemTransfused cellsContext of transfusionRed blood cellsTransfusion therapyObservational studyImmune responseAdditional antibodiesCoagulation factorsAlloimmunizationClinical barriersBlood cellsRecent mechanistic studiesRecipientsTransfusionPatientsPotential causesAntigenAntibodiesMicrobial pathogensCellsResponse